Variation of Heart-to-mediastinal Ratio in (123)I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2011 Jan 12

PMID 21221858

Citations 10

Authors

Wengen Chen

Qi Cao

Vasken Dilsizian

Affiliations

Soon will be listed here.

Abstract

Studies have repeatedly shown the utility of (123)I-mIBG cardiac sympathetic imaging for identifying symptomatic heart failure patients most likely to experience adverse cardiac events. Delayed heart-to-mediastinal ratio (H/M) and washout rate derived from meta-iodobenzylguanidine (mIBG) scintigraphy have been used to monitor response to medical treatment. However, there is great variation of H/M ratio among publications from various institutions. The current article systemically reviews factors that can potentially affect H/M ratio, particularly the acquisition parameters, and proposes new approaches and/or procedures to standardize the imaging procedure and minimize the variation of H/M among institutions.

Citing Articles

I-mIBG: Simplicity and reproducibility.

Curl K, Hansen C J Nucl Cardiol. 2018; 26(5):1566-1568.

PMID: 29380284 DOI: 10.1007/s12350-018-1196-9.

Relationship of left ventricular global longitudinal strain with cardiac autonomic denervation as assessed by I-mIBG scintigraphy in patients with heart failure with reduced ejection fraction submitted to cardiac resynchronization therapy :....

Cruz M, Abreu A, Portugal G, Santa-Clara H, Cunha P, M Oliveira M J Nucl Cardiol. 2017; 26(3):869-879.

PMID: 29209951 DOI: 10.1007/s12350-017-1148-9.

Standardization of I--iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications.

Nakajima K, Verschure D, Okuda K, Verberne H Clin Transl Imaging. 2017; 5(3):255-263.

PMID: 28596948 PMC: 5437131. DOI: 10.1007/s40336-017-0230-2.

SPECT and PET in ischemic heart failure.

Angelidis G, Giamouzis G, Karagiannis G, Butler J, Tsougos I, Valotassiou V Heart Fail Rev. 2017; 22(2):243-261.

PMID: 28150111 DOI: 10.1007/s10741-017-9594-7.

Iodine-123 metaiodobenzylguanidine scintigraphy for the assessment of cardiac sympathetic innervation and the relationship with cardiac autonomic function in healthy adults using standardized methods.

Asghar O, Arumugam P, Armstrong I, Ray S, Schmitt M, Malik R Nucl Med Commun. 2016; 38(1):44-50.

PMID: 27898646 PMC: 5131722. DOI: 10.1097/MNM.0000000000000608.

References

Henderson E, Kahn J, Corbett J, Jansen D, Pippin J, Kulkarni P . Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78(5 Pt 1):1192-9. DOI: 10.1161/01.cir.78.5.1192. View

Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M . Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006; 13(1):34-42. DOI: 10.1016/j.nuclcard.2005.11.009. View

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View

Himura Y, Felten S, Kashiki M, Lewandowski T, Delehanty J, Liang C . Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation. 1993; 88(3):1299-309. DOI: 10.1161/01.cir.88.3.1299. View

Carrio I, Cowie M, Yamazaki J, Udelson J, Camici P . Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010; 3(1):92-100. DOI: 10.1016/j.jcmg.2009.07.014. View

Nakajo M, Shimabukuro K, Yoshimura H, YONEKURA R, Nakabeppu Y, Tanoue P . Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med. 1986; 27(1):84-9. View

Haider N, Baliga R, Chandrashekhar Y, Narula J . Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovasc Imaging. 2010; 3(1):71-5. DOI: 10.1016/j.jcmg.2009.11.002. View

Bohm M, La Rosee K, Schwinger R, Erdmann E . Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995; 25(1):146-53. DOI: 10.1016/0735-1097(94)00353-r. View

Dae M, De Marco T, Botvinick E, OConnell J, Hattner R, Huberty J . Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med. 1992; 33(8):1444-50. View

10.

Flotats A, Carrio I . Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004; 11(5):587-602. DOI: 10.1016/j.nuclcard.2004.07.007. View

11.

Verberne H, Brewster L, Somsen G, van Eck-Smit B . Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008; 29(9):1147-59. DOI: 10.1093/eurheartj/ehn113. View

12.

Wieland D, Brown L, Rogers W, Worthington K, Wu J, Clinthorne N . Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981; 22(1):22-31. View

13.

Verberne H, Habraken J, van Eck-Smit B, Agostini D, Jacobson A . Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2007; 35(3):547-53. PMC: 2275776. DOI: 10.1007/s00259-007-0611-2. View

14.

Kioka H, Yamada T, Mine T, Morita T, Tsukamoto Y, Tamaki S . Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007; 93(10):1213-8. PMC: 2000924. DOI: 10.1136/hrt.2006.094524. View

15.

Agostini D, Verberne H, Burchert W, Knuuti J, Povinec P, Sambuceti G . I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2007; 35(3):535-46. DOI: 10.1007/s00259-007-0639-3. View

16.

Sisson J, Wieland D, Sherman P, Mangner T, Tobes M, Jacques Jr S . Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987; 28(10):1620-4. View

17.

Gerson M, Craft L, McGuire N, Suresh D, Abraham W, Wagoner L . Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002; 9(6):608-15. DOI: 10.1067/mnc.2002.127717. View

18.

Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper L, Grelle I . Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997; 38(3):447-51. View

19.

Kline R, Swanson D, Wieland D, Thrall J, Gross M, Pitt B . Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981; 22(2):129-32. View

20.

Backs J, Haunstetter A, Gerber S, Metz J, Borst M, Strasser R . The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol. 2001; 33(3):461-72. DOI: 10.1006/jmcc.2000.1319. View